Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Fosamax Study Shows Benefit Vs. Actonel; Aventis/P&G Fault Endpoint

This article was originally published in The Pink Sheet Daily

Executive Summary

Head-to-head study of the osteoporosis agents used bone mineral density as primary endpoint; competitors Sanofi-Aventis/P&G maintain fracture is appropriate efficacy measure. Merck study authors say 50,000 patients would be needed to power a trial for fracture risk.

You may also be interested in...



Amgen's Phase III Osteoporosis Study Is Company's Largest Clinical Program

Clinical trials for Amgen's bone loss therapy AMG 162 will look at the entire spectrum of bone health, VP-R&D Perlmutter says. Phase II studies demonstrated lower incidence of dyspepsia and more rapid absorption than Fosamax, he says.

Amgen's Phase III Osteoporosis Study Is Company's Largest Clinical Program

Clinical trials for Amgen's bone loss therapy AMG 162 will look at the entire spectrum of bone health, VP-R&D Perlmutter says. Phase II studies demonstrated lower incidence of dyspepsia and more rapid absorption than Fosamax, he says.

Roche/GSK Preparing Boniva NDA For Once-Quarterly I.V. Formulation

Filing is planned for late 2004/early 2005 based on positive Phase III results. I.V. infusion formulation of ibandronate would be the first injectable bisphosphonate for osteoporosis, administered once every two or three months.

Topics

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel